FOLR1 and cancer: Furthermore, our study confirmed pH-responsive RNA nanoparticles as a viable strategy for receptor-selective drug delivery to cancer cells with high FRα expression, which may offer an effective approach for the treatment of cancers driven by aberrant signaling through PI3K.